EVH Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of -3.53% compared to Evolent Health's net margin of -1.05%. Evolent Health's return on equity of -5.92% beat Astrana Health's return on equity of 9.13%.

Evolent Health has a consensus price target of $15.46, signalling upside risk potential of 63.1%. On the other hand Astrana Health has an analysts' consensus of $52.3000 which suggests that it could grow by 76.33%. Given that Astrana Health has higher upside potential than Evolent Health, analysts believe Astrana Health is more attractive than Evolent Health.

Evolent Health has a beta of 1.493, which suggesting that the stock is 49.272% more volatile than S&P 500. In comparison Astrana Health has a beta of 1.297, suggesting its more volatile than the S&P 500 by 29.713%.

Evolent Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolent Health pays -32.59% of its earnings as a dividend. Astrana Health pays out -- of its earnings as a dividend.

Evolent Health quarterly revenues are $646.5M, which are smaller than Astrana Health quarterly revenues of $665.2M. Evolent Health's net income of -$22.8M is lower than Astrana Health's net income of -$7M. Notably, Evolent Health's price-to-earnings ratio is -- while Astrana Health's PE ratio is 33.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health is 0.43x versus 0.69x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Biote has a net margin of -3.53% compared to Evolent Health's net margin of 20.83%. Evolent Health's return on equity of -5.92% beat Biote's return on equity of --.

Evolent Health has a consensus price target of $15.46, signalling upside risk potential of 63.1%. On the other hand Biote has an analysts' consensus of $9.87 which suggests that it could grow by 140.81%. Given that Biote has higher upside potential than Evolent Health, analysts believe Biote is more attractive than Evolent Health.

Evolent Health has a beta of 1.493, which suggesting that the stock is 49.272% more volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Evolent Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolent Health pays -32.59% of its earnings as a dividend. Biote pays out 262.18% of its earnings as a dividend.

Evolent Health quarterly revenues are $646.5M, which are larger than Biote quarterly revenues of $51.4M. Evolent Health's net income of -$22.8M is lower than Biote's net income of $10.7M. Notably, Evolent Health's price-to-earnings ratio is -- while Biote's PE ratio is 15.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health is 0.43x versus 0.71x for Biote. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of -3.53% compared to Evolent Health's net margin of 13.04%. Evolent Health's return on equity of -5.92% beat Cryo-Cell International's return on equity of --.

Evolent Health has a consensus price target of $15.46, signalling upside risk potential of 63.1%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 32.81%. Given that Evolent Health has higher upside potential than Cryo-Cell International, analysts believe Evolent Health is more attractive than Cryo-Cell International.

Evolent Health has a beta of 1.493, which suggesting that the stock is 49.272% more volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.570, suggesting its less volatile than the S&P 500 by 42.967%.

Evolent Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 7.81% to investors and pays a quarterly dividend of $0.25 per share. Evolent Health pays -32.59% of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.

Evolent Health quarterly revenues are $646.5M, which are larger than Cryo-Cell International quarterly revenues of $8.1M. Evolent Health's net income of -$22.8M is lower than Cryo-Cell International's net income of $1.1M. Notably, Evolent Health's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is 135.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health is 0.43x versus 1.64x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of -3.53% compared to Evolent Health's net margin of -12.84%. Evolent Health's return on equity of -5.92% beat P3 Health Partners's return on equity of -26.35%.

Evolent Health has a consensus price target of $15.46, signalling upside risk potential of 63.1%. On the other hand P3 Health Partners has an analysts' consensus of $0.63 which suggests that it could grow by 246.45%. Given that P3 Health Partners has higher upside potential than Evolent Health, analysts believe P3 Health Partners is more attractive than Evolent Health.

Evolent Health has a beta of 1.493, which suggesting that the stock is 49.272% more volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Evolent Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolent Health pays -32.59% of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

Evolent Health quarterly revenues are $646.5M, which are larger than P3 Health Partners quarterly revenues of $362.1M. Evolent Health's net income of -$22.8M is higher than P3 Health Partners's net income of -$46.5M. Notably, Evolent Health's price-to-earnings ratio is -- while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolent Health is 0.43x versus 0.02x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.